WO2001035946A3 - Intranasal administration of raloxifene and tamoxifen - Google Patents

Intranasal administration of raloxifene and tamoxifen Download PDF

Info

Publication number
WO2001035946A3
WO2001035946A3 PCT/US2000/027394 US0027394W WO0135946A3 WO 2001035946 A3 WO2001035946 A3 WO 2001035946A3 US 0027394 W US0027394 W US 0027394W WO 0135946 A3 WO0135946 A3 WO 0135946A3
Authority
WO
WIPO (PCT)
Prior art keywords
raloxifene
tamoxifen
derivatives
compounds
intranasal administration
Prior art date
Application number
PCT/US2000/027394
Other languages
French (fr)
Other versions
WO2001035946A2 (en
Inventor
Anwar A Hussain
Lewis W Dittert
Original Assignee
New Millennium Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Millennium Pharmaceutical filed Critical New Millennium Pharmaceutical
Priority to AU79935/00A priority Critical patent/AU7993500A/en
Publication of WO2001035946A2 publication Critical patent/WO2001035946A2/en
Publication of WO2001035946A3 publication Critical patent/WO2001035946A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention provides a method of rapidly and reliably delivering raloxifene or tamoxifen, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of breast cancer. The present invention further provides intranasal pharmaceutical compositions comprising raloxifene or tamoxifen, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other compounds.
PCT/US2000/027394 1999-11-15 2000-10-05 Intranasal administration of raloxifene and tamoxifen WO2001035946A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79935/00A AU7993500A (en) 1999-11-15 2000-10-05 Intranasal administration of raloxifene and tamoxifen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16496599P 1999-11-15 1999-11-15
US60/164,965 1999-11-15

Publications (2)

Publication Number Publication Date
WO2001035946A2 WO2001035946A2 (en) 2001-05-25
WO2001035946A3 true WO2001035946A3 (en) 2002-01-10

Family

ID=22596847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027394 WO2001035946A2 (en) 1999-11-15 2000-10-05 Intranasal administration of raloxifene and tamoxifen

Country Status (2)

Country Link
AU (1) AU7993500A (en)
WO (1) WO2001035946A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009040A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Benzofuran compounds, compositions, and methods
EP0747054A2 (en) * 1995-06-06 1996-12-11 Eli Lilly And Company Methods for minimizing bone loss
EP0838464A1 (en) * 1996-10-25 1998-04-29 Eli Lilly And Company Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators
WO1998029114A1 (en) * 1996-12-30 1998-07-09 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
EP0897722A1 (en) * 1997-08-21 1999-02-24 Eli Lilly And Company Benzo(b)thiophene derivatives for inhibiting fibrous inflammatory diseases and Riedel's thyroiditis
WO1999051096A1 (en) * 1998-04-08 1999-10-14 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000059517A1 (en) * 1999-04-07 2000-10-12 Roger Williams Hospital Ceramide and chemotherapeutic agents for inducing cell death

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009040A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Benzofuran compounds, compositions, and methods
EP0747054A2 (en) * 1995-06-06 1996-12-11 Eli Lilly And Company Methods for minimizing bone loss
EP0838464A1 (en) * 1996-10-25 1998-04-29 Eli Lilly And Company Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators
WO1998029114A1 (en) * 1996-12-30 1998-07-09 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
EP0897722A1 (en) * 1997-08-21 1999-02-24 Eli Lilly And Company Benzo(b)thiophene derivatives for inhibiting fibrous inflammatory diseases and Riedel's thyroiditis
WO1999051096A1 (en) * 1998-04-08 1999-10-14 Eli Lilly And Company Pulmonary and nasal delivery of raloxifene
WO1999062537A1 (en) * 1998-06-04 1999-12-09 The Rockefeller University Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins
WO2000059517A1 (en) * 1999-04-07 2000-10-12 Roger Williams Hospital Ceramide and chemotherapeutic agents for inducing cell death

Also Published As

Publication number Publication date
AU7993500A (en) 2001-05-30
WO2001035946A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
GB2367005A (en) Pharmaceutical formulations and methods comprising intranasal morphine
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
AP1760A (en) Platinum derivative pharmaceutical formulations.
WO2002083079A3 (en) Aerosol compositions containing formoterol for delivery to the lungs via nebulization
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
IS6319A (en) Indolyl-3-glyoxy acid derivatives containing useful therapeutic properties
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
AP2003002763A0 (en) Controlled release formulations for oral administration
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
WO2000048445A3 (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
CA2432177A1 (en) Drug for prevention and/or therapy of endometriosis
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
WO2001035946A3 (en) Intranasal administration of raloxifene and tamoxifen
MY122477A (en) Sertraline oral concentrate
WO2004050019A3 (en) Method and compositions for treating anxiety
GB0122257D0 (en) Simplified sarcodictyin derivatives
HU0100122D0 (en) Use of tiludronic acid and derivatives thereof in poultry for preparation of a medicinal product for preventing and treating osteoporosis
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP